



### Company Overview

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as graft-vs-host disease (GvHD) and NASH.

### First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated

Apr 6 2020, 6:00 AM EDT

### CytoDyn CEO Dr. Pourhassan Appearance on Fox Business Network Rescheduled to April 8 Same Time (11am PT); CytoDyn will Reveal Today the Name of the Hospital and the Physician who Treated 10 Patients During an Interview on Seattle-Affiliate of CBS News which Will Air Between 5-6:30 p.m. PT

Apr 3 2020, 1:48 PM EDT

### CytoDyn Files Request with FDA for Preliminary Meeting for Breakthrough Therapy Designation for Leronlimab in the Treatment of Cancer

Apr 3 2020, 6:15 AM EDT

### Stock Overview

Symbol	CYDY
Exchange	OTCQB
Market Cap	1.27b
Last Price	\$2.95
52-Week Range	\$0.26 - \$3.50

04/06/2020 03:59 PM EDT

### Management Team

**Nader Z. Pourhassan, PhD**  
Director, President and CEO

**Craig S. Eastwood, CPA**  
Chief Financial Officer

**Nitya G. Ray, PhD**  
Chief Technology Officer - Head of Process Sciences, Manufacturing & Supply Chain

**Jacob P. Lalezari, MD**  
Interim Chief Medical Officer

**Brendan P. Rae, PhD, JD**  
Senior Vice President of Business Development

---

### CytoDyn Inc.

1111 Main Street  
Suite 660  
Vancouver, WA 98660

---

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.